Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 1
1982 1
1983 3
1984 2
1985 1
1986 1
1987 1
1988 1
1989 3
1990 12
1991 8
1992 6
1993 9
1994 12
1995 14
1996 21
1997 22
1998 20
1999 15
2000 29
2001 29
2002 14
2003 39
2004 31
2005 23
2006 34
2007 39
2008 63
2009 49
2010 54
2011 78
2012 102
2013 114
2014 129
2015 172
2016 170
2017 186
2018 199
2019 236
2020 314
2021 340
2022 361
2023 456
2024 242

Text availability

Article attribute

Article type

Publication date

Search Results

3,244 results

Results by year

Filters applied: . Clear all
Page 1
Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study.
Yan XQ, Ye MJ, Zou Q, Chen P, He ZS, Wu B, He DL, He CH, Xue XY, Ji ZG, Chen H, Zhang S, Liu YP, Zhang XD, Fu C, Xu DF, Qiu MX, Lv JJ, Huang J, Ren XB, Cheng Y, Qin WJ, Zhang X, Zhou FJ, Ma LL, Guo JM, Ding DG, Wei SZ, He Y, Guo HQ, Shi BK, Liu L, Liu F, Hu ZQ, Jin XM, Yang L, Zhu SX, Liu JH, Huang YH, Xu T, Liu B, Sun T, Wang ZJ, Jiang HW, Yu DX, Zhou AP, Jiang J, Luan GD, Jin CL, Xu J, Hu JX, Huang YR, Guo J, Zhai W, Sheng XN. Yan XQ, et al. Among authors: zhou ap. Ann Oncol. 2024 Feb;35(2):190-199. doi: 10.1016/j.annonc.2023.09.3108. Epub 2023 Oct 21. Ann Oncol. 2024. PMID: 37872020 Free article. Clinical Trial.
Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials.
Sheng X, Wang L, He Z, Shi Y, Luo H, Han W, Yao X, Shi B, Liu J, Hu C, Liu Z, Guo H, Yu G, Ji Z, Ying J, Ling Y, Yu S, Hu Y, Guo J, Fang J, Zhou A, Guo J. Sheng X, et al. Among authors: zhou a. J Clin Oncol. 2024 Apr 20;42(12):1391-1402. doi: 10.1200/JCO.22.02912. Epub 2023 Nov 21. J Clin Oncol. 2024. PMID: 37988648 Free PMC article. Clinical Trial.
SEC61G assists EGFR-amplified glioblastoma to evade immune elimination.
Zeng K, Zeng Y, Zhan H, Zhan Z, Wang L, Xie Y, Tang Y, Li C, Chen Y, Li S, Liu M, Chen X, Liang L, Deng F, Song Y, Zhou A. Zeng K, et al. Among authors: zhou a. Proc Natl Acad Sci U S A. 2023 Aug 8;120(32):e2303400120. doi: 10.1073/pnas.2303400120. Epub 2023 Jul 31. Proc Natl Acad Sci U S A. 2023. PMID: 37523556 Free PMC article.
Cutaneous Coccidiomycosis.
Brown M, Zhou AE, Jaffe DF, Pfau RG. Brown M, et al. Among authors: zhou ae. Am J Dermatopathol. 2024 Feb 1;46(2):111-113. doi: 10.1097/DAD.0000000000002601. Epub 2023 Dec 6. Am J Dermatopathol. 2024. PMID: 38055960
PARP inhibition and immunotherapy: a promising duo in fighting cancer.
Phillipps J, Zhou AY, Butt OH, Ansstas G. Phillipps J, et al. Among authors: zhou ay. Transl Cancer Res. 2023 Sep 30;12(9):2433-2437. doi: 10.21037/tcr-23-726. Epub 2023 Aug 3. Transl Cancer Res. 2023. PMID: 37859734 Free PMC article. No abstract available.
T-BET and EOMES sustain mature human NK cell identity and antitumor function.
Wong P, Foltz JA, Chang L, Neal CC, Yao T, Cubitt CC, Tran J, Kersting-Schadek S, Palakurty S, Jaeger N, Russler-Germain DA, Marin ND, Gang M, Wagner JA, Zhou AY, Jacobs MT, Foster M, Schappe T, Marsala L, McClain E, Pence P, Becker-Hapak M, Fisk B, Petti AA, Griffith OL, Griffith M, Berrien-Elliott MM, Fehniger TA. Wong P, et al. Among authors: zhou ay. J Clin Invest. 2023 Jul 3;133(13):e162530. doi: 10.1172/JCI162530. J Clin Invest. 2023. PMID: 37279078 Free PMC article.
23ME-00610, a genetically informed, first-in-class antibody targeting CD200R1 to enhance antitumor T cell function.
Fenaux J, Fang X, Huang YM, Melero C, Bonnans C, Lowe EL, Palumbo T, Lay C, Yi Z, Zhou A, Poggio M, Chung WJ, Majeed SR, Glatt D, Chen A, Schmidt M, Lee CC. Fenaux J, et al. Among authors: zhou a. Oncoimmunology. 2023 Jun 5;12(1):2217737. doi: 10.1080/2162402X.2023.2217737. eCollection 2023. Oncoimmunology. 2023. PMID: 37288324 Free PMC article.
3,244 results